

# Agenda

# • COVID analyses update

- Recap from 3/2/22 Mtg; correlations update
- Modeling of QBR -findings
- RRIP RY 2024 draft policy discussion
  - Improvement and Attainment
  - Patient Adversity Index (PAI)
- eCQM update



# **Overview of COVID Analysis and Adjustment Updates**




3

# MHAC and RRIP Recap

- Reviewed use of concurrent norms with COVID patients included with PMWG, CMMI, and Commissioners
- Providing by hospital revenue adjustments modeled using FY 2021 for budgetary purposes (see attached Excel file with hospital results modeled)
- Correlated MHAC scores and readmission rates with percent COVID days by hospital



# % COVID Pt Days and Model 2 MHAC Scores (Concurrent Norms)




- As % COVID pt days increases, MHAC scores increase
- R<sup>2</sup>= 0.1927
- P-Value= 0.004
- Removes UMROI and Levindale as an outlier because it had ~0% COVID patients

Although the relationship is statistically significant, it only explains 19% of the variation in performance and the Model does not appear to penalize hospitals for having more COVID patients.



# % COVID Pt Days and Model 2 RRIP Scores (Concurrent norms)



- As % COVID Pt Days increases, readmission rates decrease
- R<sup>2</sup>=.0699
- P-value= .087
- Removes UMROI and Levindale as an outlier because they had ~0% COVID patients

Although the relationship is statistically significant, it only explains 7% of the variation in performance and the Model does not appear to penalize hospitals for having more COVID patients.



# MHAC and RRIP Correlation Conclusion

- MHAC- % COVID Pt Days explains only 19% of the variation in Model 2 MHAC scores
- RRIP- % COVID Pt Days explains only 7% of the variation in Model 2 Readmission rates
- Model 2 does not appear to penalize hospitals for having more COVID patient days for both programs
- Therefore, Staff proposes to use Model 2 for RY23 Quality adjustments



# **Disparity Gap**

- Given this is an upside improvement only program, staff propose minimal changes
  - Only change will be removal of COVID patients from performance period



# MHAC Revenue Adjustment Scale

- Staff modeled changing the MHAC revenue adjustment scale to reflect the changes in scores:
  - Currently with modeling the hold harmless zone for Model 2 is from 56-66%
  - Will update with final results so that the hold harmless zone is a 10 percentage point gap centered around the state average



# RY 23 Quality-Based Reimbursement: COVID Analyses




# RY 2023-2024 QBR

#### Performance Measures

Standardized Measure Scores


QBR Measures by Domain:

- Person and Community Engagement (PCE)(9 Measures: 8 HCAHPS categories; Follow-up after chronic conditions exacerbation (Medicare)) NEW proposed RY 2024 update: add HCAHPS linear score =10% QBR score (20% of PCE domain)
- Safety (6 Measures: 5 CDC NHSN HAI Categories; All-payer PSI 90)
- Clinical Care (Inpatient Mortality, THA/TKA Complication)



Individual Measures are Converted to 0-10 Points:

Points for Attainment Compare Performance to a National Threshold (median) and Benchmark (top 5%)



Points for Improvement Compare Performance to Base (historical perf) and Benchmark Hist. Perf Benchmark



Final Points are Better of Improvement or Attainment

#### Hospital QBR Score & Revenue Adjustments

Hospital QBR Score is Sum of Earned Points / Possible Points with Domain Weights Applied


Scale Ranges from 0-80%

Max Penalty 2% & Reward +2% NEW proposed RY 2024 update: Allow hospitals to receive upfront investment for HCAHPS improvement with 1 year payback.


Abbreviated Pre- Set Scale	QBR Score	Financial Adjustment
Max Penalty	0%	-2.00%
	10%	-1.51%
	20%	-1.02%
	30%	-0.54%
Penalty/Reward		
Cutpoint	41%	0.00%
	50%	0.46%
	60%	0.97%
	70%	1.49%
Max Reward	80%+	2.00%

# QBR Modeling: Preliminary Maryland Hospital Scores

- Modeled preliminary QBR scores using most recently available data
  - Care Compare January 2022 Release (July 2020-March 2021)
  - CY 2021 YTD for mortality, PSI (without COVID), and timely follow-up



# National HCAHPS Change (n=2541 hospitals)



Nationally there has been a reduction in HCAHPS measure scores. Analyses from BRG show similar reductions in the safety domain.



3

# QBR Modeling: Cut-point Analyses

CMS VBP 39.45% 35.56% 37.43%	QBR Weighted 42.67% 39.93%	QBR Weighted w/o Clinical Care 
35.56%	39.93%	
37.43%	12 00%	
	42.00%	
38.12%	40.90%	
38.49%	39.63%	
33.88%	36.60%	33.08%
ional Scores ecent data	25.68%*	27.08%
om FFY21	10.92%	6.00%
	33.88% onal Scores cent data om FFY21	33.88% 36.60% onal Scores 25.68%*


score for MD hospitals was used.

Prior to COVID (pre FFY21) average national performance was 41%. Commissioners established this as cut point.

Staff proposal: Reduce the 41% cutpoint by 6-11% to reflect lower national scores.



# **Revenue Adjustment Modeling**





# **Update on Inpatient Mortality**

- Current QBR modeling does not include any changes for COVID
  - Because performance standards are also adjusted, do not anticipate significant changes in the mortality scoring under different models
     Initial models

Model	Description	Base Period	Performance Period	Risk Adjustment Period
Model 1	Original base period normative value	01/01/2019 – 12/31/2019	07/01/2020 - 06/30/2021	01/01/2019 – 12/31/2019
Model 2	Concurrent normative values including COVID-19 patients	01/01/2019 – 12/31/2019	07/01/2020 - 06/30/2021	07/01/2020 - 06/30/2021
Model 2A	Concurrent normative values including COVID-19 patients and included COVID as covariate	01/01/2019 – 12/31/2019	07/01/2020 - 06/30/2021	07/01/2020 - 06/30/2021
Model 3	Concurrent normative values excluding COVID-19 patients	01/01/2019 – 12/31/2019	07/01/2020 - 06/30/2021	07/01/2020 - 06/30/2021
Model 3A	Concurrent normative values excluding COVID-19 patients and using 80% cumulative death threshold from Model 2	01/01/2019 – 12/31/2019	07/01/2020 – 06/30/2021	07/01/2020 - 06/30/2021

Staff prefers Model 2 since it aligns with MHAC and RRIP; Model 2 controlling for percent COVID days shows lower correlations, similar to MHAC and RRIP.

showed high correlations between hospital mortality rates and percent COVID days. Thus, reran models controlling for percent COVID days at the hospital.



# **QBR Next Steps**

- Review retrospective adjustments with Commissioners and CMMI
- Finalize mortality analysis with concurrent norms and rerun modeling using whole CY 2021
- Adjust QBR revenue adjustment scale by estimated national decline



# RY 2024 RRIP Draft Policy Discussion



18

# **RY 2024 RRIP Considerations**

- Measure: No proposed measure updates
  - Reminder HSCRC has removed pediatric oncology cases in RY 2023 onward, per the measure stewards.
- Improvement Target: Continue with the RRIP redesign goal of a 7.5 percent improvement from 2018-2023
  - CY2022 Improvement goal: 6.05%
- Attainment Target: No updates at this time
- Disparity Gap: TBD
- New measure for **Monitoring Report**: EDAC
- COVID changes
  - Use FY 2021 (i.e., post-covid time period) for statewide norms to allow better prospective tracking. Still measure improvement from CY 2018.
  - Additional retrospective changes will be considered to account for COVID



# eCQM Data Collection Update - from CRISP/Medisolv Partners



20



# Hospital eCQM Data Collection

Peggy Oehlmann, Program Manager for Quality & Transformation, CRISP Zahid Butt, MD, CEO, Medisolv




- CRISP and Medisolv supporting HSCRC goals for hospital reporting of eCQMs
- Optional submission of 2021 measures in Spring 2022
- Hospitals required to submit 4 measures quarterly, with the first submission window opening in July 2022 for Q1 & Q2 2022
- Data submitted via Quality Reporting Document Architecture (QRDA) I
- For 2023 and beyond, ED-2 and eOPI-1 are required, other required measures TBD
- Data to be uploaded to Medisolv ENCOR portal via CRISP Portal (ULP)
- While these measures align with federal IQR measures, it does not replace IQR Reporting

Note: Timelines for data submission for this initiative are separate and distinct from federal IQR submission.



# eCQM Reporting for MD Hospitals CY 2021-2023

Performance Year	CY 2021	CY 2022	CY 2023
# eCQMs/Reporting Period	4 eCQMs submitted to CMS 2 qtrs. of data	2 required + 2 optional eCQMs 4 qtrs. of data submitted to CRISP/Medisolv	2 required eCQMs 4 qtrs of data submitted to CRISP/Medisolv. Additional eCQM requirements TBD
Data Submission	1/15/2022 - 3/31/2022	See # 2	TBD
ED-2: Decision to Admit to Admission Median Time	Optional	Required	Required
PC-01: Elective Delivery	Optional	Optional	TBD
PC-02: Cesarean Birth	Optional	Optional	TBD
PC-05: Exclusive Breast Milk Feeding	Optional	Optional	TBD
PC-06: Unexpected complications in term newborns	Optional	Optional	TBD
STK-2: Discharged on Antithrombotic Therapy	Optional	Optional	TBD
STK-3: Anticoagulation Therapy for A. Fibrillation /Flutter	Optional	Optional	TBD
STK-5: Antithrombotic by Day 2	Optional	Optional	TBD
STK-6: Discharged on Statin Medication	Optional	Optional	TBD
VTE-1: VTE Prophylaxis	Optional	Optional	TBD
VTE-2: ICU VTE Prophylaxis	Optional	Optional	TBD
OPI-01 Safe use of Opioids	Optional	Required	Required
Severe Hypoglycemia			TBD
Severe Hyperglycemia			TBD <sup>23</sup>



- 1. Calendar Year 2021 "Test Run" Submission of Data- Hospitals to optionally submit to CRISP/Medisolv the same QRDA 1 files they submitted to CMS in Spring 2022
  - 4 eCQM's with 2 quarters of CY 2021 performance period data
  - 27 Hospitals indicated willingness to submit 2021 pilot data
  - If interested in pilot, contact Ken McCormick (<u>kmccormick@medisolv.com</u>) or Jenna Pickard (jpickard@medisolv.com)
- 2. Calendar Year 2022 Required Data Submission- Starting with Q 1, 2022 performance period, all hospitals submit to CRISP/Medisolv quarterly data: 2 required eCQM's and 2 optional eCQM's from the table below according to the following submission schedule:

#### **Performance Period Submission Windows**

Q1 2022 data	Open: 7/15/2022	Close: 09/30/2022
Q2 2022 data	Open: 7/15/2022	Close: 09/30/2022
Q3 2022 data	Open: 10/15/2022	Close: 12/30/2022
Q4 2022 data	Open: 1/15/2023	Close: 3/31/2023



Link to Medisolv platform will be available on CRISP Portal (eg, ULP)

Three Sections of the platform include:

- Medisolv Submission Platform (MSP) for uploading data
- Drill down to Measure performance detail for Hospital staff
- Aggregate performance data for each hospital by measure

### CRISP Portal (ULP) Access

# HOME			
	Search Applications & Rep	orts	хQ
ENCOR Electronic Measures			Health # 2
eb			
р р			
OID Information			
Version: 2020 (EH, EC) ~			
OID Based Grouping Code Listing			
OID Based Gr	ouping		0
Drag a column header here to group by that column			
Element Description Status Type o	Did N	Negation Measure Type	and the second se
Madication: Statin Medication: Statin			CMS105v9
Procedure: Neonatal Severe Respiratory Procedures Procedures Procedures	2.16.840.1.113762.1.4.1029.160 F	False EH	ePC06v1
Medication: Warfarin Medication: Warfarin Ordered Medication	2.16.840.1.113883.3.117.1.7.1.232		CMS108v9, CMS190v9
Laboratory Test: Creatinine lab test Creatinine lab test Creatinine lab test	2.16.840.1.113883.3.666.5.2363	False EH	CM5529v1
Diagnostic study: Moderate Neurological Complications with LOS Procedures Diagnostic study: Moderate Neurological Complications with LOS	2.16.840.1.113762.1.4.1029.184 K	false EH	ePC06v1
Version ENCOR-e prod crisp v6.79.1.3			medisolv •
			medisolv 🍾 🧹
			medisolv 🖌 🤟



### Measure aggregate results for HSCRC Reporting

medisolv CRISP ~	Applications	B Justin DIStefano V
MEASURES SCORECARDS		
Measures		
♀     2/1/2019 - 2/28/2022     Image: Quarterly ∨		

Measure Title <b>≑</b>	Trend	Domain 🗢	CMS ID 🗢	Q1-2022 🖨	Q4-2021 🖨	Q3-2021 🖨	Q2-2021 🖨	Q1-2021 🖨	Q4-20
<b>T</b>		<b>T</b>	<b>T</b>	<b>T</b>	<b>T</b>	<b>T</b>	<b>T</b>	<b>T</b>	<b>T</b>
Anticoagulation Therapy for Atrial Fibrillation/Flutter	1	Quality	CMS71			25	55.56	46.15	
Antithrombotic Therapy By End of Hospital Day 2	1	Quality	CMS72			0	0	0	
Covid Measure	*	Quality	CMS988						-
<ul> <li>Discharged on Antithrombotic Therapy</li> </ul>	*	Quality	CMS104			66.67	82.61	85.96	-
<ul> <li>Discharged on Statin Medication</li> </ul>	•	Quality	CMS105	3	3	71.11	82.61	80.7	
Elective Delivery	*	Quality	ePC01	-	-		-		
Exclusive Breast Milk Feeding	1	Quality	CMS9					2.85	1.0
Hybrid Hospital-Wide Readmission (HWR) Measure with Claims and Electronic Health Record Data	*	Quality	CMS529	-	÷	-	÷	-	-
Intensive Care Unit Venous Thromboembolism Prophylaxis	*	Safety	CMS190		-	0	0	0	-
Safe Use of Opioids - Concurrent Prescribing	*	Cost	CMS506		100	17.58	18.48	19.39	-

1 - 10 of 11 items





### Medisolv Submission Portal (MSP)

ENCOR Medisol	v Submission	Platform							Med	isolv 🇱 - 2-
Home Previous Uploa	ds									
Upload QRDA File Organization	es	Hospital/Facili	ty							
	Hospital	• A	Hospital	•						
Select files									Dr	op files here to upload
Files may be in either .zip file or .xr	<del>ni</del> format.									
Previous Uploads										
File Name				Status	Upload Date	Actions				
fog8a1ba-gdb5-426c-b8	45-b7a3ed4003e8	_210011_qrda_202	20108095728.zip	Warnings	2/1/2022 08:24 AM	Publish	Download	Delete	Warnings/Errors	Measure Results
fog8a1ba-9db5-426c-b8	45-b7a3ed4003e8	_210011_qrda_202	20109095728.zip	Errors	2/1/2022 08:18 AM	Publish	Download	Delete	Warnings/Errors	Measure Results
$ w  \rightarrow   \mathbf{x}   \rightarrow   w $	10 🔹 items	s per page								1 - 2 of 2 items <b>Ö</b>





# Medisolv ENCOR – EH Home Page

Rate Measures For 2021 Calendar Year (EH) 🛛			View EH eCQM R
Measure	Rate	In Numerator / In Denomin	ator Only
CMS104v9: Discharged on Antithrombotic Therapy	100.00%	1	
CMS105v9: Discharged on Statin Medication	100.00%	(	
CMS190v9: Intensive Care Unit Venous Thromboembolism Prophylaxis	100.00%	18	
CMS71v10: Anticoagulation Therapy for Atrial Fibrillation/Flutter	100.00%	1	
CMS72v9: Antithrombotic Therapy By End of Hospital Day 2	100.00%		
CMS108v9: Venous Thromboembolism Prophylaxis	91.28%	157	
ePC01v9: Elective Delivery	80.00%	4	1
ePC02v2: Cesarean Birth	42.42%	14	19
CMS9v9: Exclusive Breast Milk Feeding	25.00%		3
CMS506v3: Safe Use of Opioids – Concurrent Prescribing	12.82%	15 102	
ePC06v1: Unexpected Complications in Term Newborns - Unstratified	0.00%	1	
ePC06v1: Unexpected Complications in Term Newborns - Severe		0	
ePC06v1: Unexpected Complications in Term Newborns - Moderate		0	
Continuous Measures For 2021 Calendar Year (EH)			
Measure		Measure Lowest / Media Population	an / Highest



### Medisolv ENCOR – EH eCQM Results

		Hospital -								Lâst EC Loa	id: 10/04/2021 10:17
	easure Res										
spital:	Demo Hospi	ital 🗸								01/01/2021 - 12	2/31/2021
gulatory	eCQMs Hybrid	d Measures Med	lisolv eCQMs	Rate Measure	Pasulte						
ran a ci	olumn header	here to group l	w that column	Kate Measur	e Kesuits						
Ø	CMS Id	TJC Id	Measure Name	eCQM Version	Initial Population	In Denominator Only	Den. Exclusions	Numerator	Denominator	Exceptions	Rate
	<b>v</b>	-	2	⊽	Q Q	Q	▼	\$		⊽ [	\♥
	CMS108v9	eVTE-1	Venous Thromboembolism Prophylaxis	2020 EH	229	15	57	157	229	9	0 91
	CM5190v9	eVTE-2	Intensive Care Unit Venous Thromboembolism Prophylaxis	2020 EH	229	0	2	18	20	0	0 100
	CMS104v9	eSTK-2	Discharged on Antithrombotic Therapy	2020 EH	2	0	0	1		1	0 100
	CM571v10	eSTK-3	Anticoagulation Therapy for Atrial Fibrillation/Flutter	2020 EH	2	0	0	1	1	1	0 100
	CMS72v9	eSTK-5	Antithrombotic Therapy By End of Hospital Day 2	2020 EH	2	0	0	1		1	0 100
	CMS105v9	eSTK-6	Discharged on Statin Medication	2020 EH	2	0	0	1		1	0 100
	ePC01v9	ePC-01	Elective Delivery	2020 EH	118	1	14	4	19	9	0 80
	ePC02v2	ePC-02	Cesarean Birth	2020 EH	118	19	3	14	30	5	0 42
	CMS9v9	ePC-05	Exclusive Breast Milk Feeding	2020 EH	4	3	0	1		4	0 25
	CMS506v3	eOPI-1	Safe Use of Opioids - Concurrent Prescribing	2020 EH	138	102	21	15	13	в	0 12
ge 1	] of 2 (13 items )	) < [1] 2 ).	AI]								Page size: 10
				Continuous Mea	sure Results						
rag a co	olumn header	here to group L	by that column								
	CMS Id	TJC Id	Measure Name	eCQM Version	Strata			Initial Population	Measure I Population	Measure Population Exclusion	Measure Observations (Minutes)
		v v		2	2			\$ Q	♥		
			Median Admit Decision Time to ED Departure Time for Admitted Patients	2020 EH	Unstratified			43	43	0	



### Medisolv ENCOR - VTE 1 Encounter Details (Medications)

ne Clinician -	- Hospi	ital - Value S	ets Cont	act Us									Last EH Load: 10/04/2 Last EC Load: 10/04/2	
tient Details	(													
Demographics	Providers	6												
Medisolv Identifie	ier		610ad1d3d6	582600914f72ffl	b		Pa	atient Identifi	îer	UN0000053978		Name	Cohen, Laila	
Birth Date			4/5/1935				Eth	thnicity		Not Hispanic or Lating	0	Race	White	
Hospital <mark>N</mark> ame			Demo Hospi	tal			Ge	ender		Female		Expired Date	2/24/2021	
CMS108v9	/9- Venous 1	Thromboembolism	n Prophylaxis	8					Result: in Nur	merator		Case Identifier: A	AC0000115752	
Conditions En	ncounters	Medications	Procedures	Lab Tests	Allergy/ADR	Medical De	evices Clinica	cal Document	tation Insurance			QRDA Export (Full Reco	ord) » BSON Export (Deidentified Full R	Reco
		B U												
								1	Medications					
Drag a column be	header here i	to aroun by that c	alumn					N	Medications					
Drag a column he Case Identifier		to group by that c	olumn Descrip	tion	Status	_	Route		Medications Start Time	End Time	Author Time	Negation Code	Documentation	U
				tion	Status	4	Televense.			and the second se		and the second sec		22.00
	Co V		Descrip	otion an 2.5 MG Oral	and the second second	19 <del>10</del> 1910	Televense.	s v 	Start Time	and the second se		and the second sec		200
Case Identifier	752 Rx	odes	Descrip P apixaba Tablet		7	red	Televense.	2 0 1 F	<b>Start Time</b> ুণ 12/28/2020 8:01:00	▼ 12/28/2020 8:02:00	▼ 12/28/2020 8:01:00	and the second sec	9	2
Case Identifier	752 Rx	odes «Norm:1364435	Descrip Descrip apixaba Tablet apixaba Tablet	an 2.5 MG Oral	administer	red	Televerse.	▼ 5	Start Time	▼ 12/28/2020 8:02:00 PM 12/29/2020 9:40:00	12/28/2020 8:01:00           PM           12/29/2020 9:39:00	and the second sec	PhaRx, PhaRxMedications: APIX2.ST2	
Case Identifier AC00001157 AC00001157	Ca           ♥           752         Rx           752         Rx           752         Rx	odes (Norm:1364435 (Norm:1364435	Descrip Descrip apixaba Tablet apixaba Tablet apixaba Tablet	an 2.5 MG Oral an 2.5 MG Oral	administer	red red	Televerse.	5 9 1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Start Time	© 12/28/2020 8:02:00 PM 12/29/2020 9:40:00 AM 12/29/2020 8:25:00	▼           12/28/2020 8:01:00           PM           12/29/2020 9:39:00           AM           12/29/2020 8:24:00	and the second sec	PhaRx, PhaRxMedications: APIX2.ST2 PhaRx, PhaRxMedications: APIX2.ST2	2
Case Identifier AC00001157 AC00001157 AC00001157	752 Rx 752 Rx 752 Rx 752 Rx	xNorm:1364435 (Norm:1364435 (Norm:1364435	Descrip Descrip apixaba Tablet apixaba Tablet apixaba Tablet apixaba Tablet apixaba Tablet	an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral	administer administer administer	red red red red	Televerse.	5 • • • • • • • • • • • • • • • • • • •	Start Time	© © 12/28/2020 8:02:00 PM 12/29/2020 9:40:00 AM 12/29/2020 8:25:00 PM 12/30/2020 8:23:00	▼           12/28/2020 8:01:00           PM           12/29/2020 9:39:00           AM           12/29/2020 8:24:00           PM           12/30/2020 8:22:00	and the second sec	PhaRx, PhaRxMedications: APIX2.ST2 PhaRx, PhaRxMedications: APIX2.ST2 PhaRx, PhaRxMedications: APIX2.ST2 PhaRx, PhaRxMedications: APIX2.ST2	2
Case Identifier AC00001157! AC00001157! AC00001157! AC00001157!	♥         ♥           752         Rx           752         Rx           752         Rx           752         Rx           752         Rx           752         Rx	odes (Norm:1364435 (Norm:1364435 (Norm:1364435 (Norm:1364435	Descrip       P       apixaba       Tablet       apixaba       Tablet       apixaba       Tablet       apixaba       Tablet       Lovasta       Tablet	an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral	The second se	red red red red red	Televerse.	5 • • • • • • • • • • • • • • • • • • •	Start Time	▼           12/28/2020 8:02:00           PM           12/29/2020 9:40:00           AM           12/29/2020 8:25:00           PM           12/30/2020 8:23:00           AM           12/30/2020 5:27:00	▼           12/28/2020 8:01:00           PM           12/29/2020 9:39:00           AM           12/29/2020 8:24:00           PM           12/30/2020 8:22:00           AM           12/30/2020 5:26:00	and the second sec	PhaRx, PhaRxMedications: APIX2.5T2	2
Case Identifier AC00001157! AC00001157! AC00001157! AC00001157!	▼         Ca           ▼         Rx           752         Rx           752         Rx           752         Rx           752         Rx           752         Rx           752         Rx	xNorm:1364435 xNorm:1364435 xNorm:1364435 xNorm:1364435 xNorm:1364435	Descrip       P       apixaba Tablet       apixaba Tablet       apixaba Tablet       apixaba Tablet       Lovasta Tablet       Lovasta Tablet	an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral atin 20 MG Oral	v       administer       administer       administer       administer       administer	red red red red red red	Televerse.	5 0 0 1 F 1 4 1 F 1 4 1 F 1 4 1 5 1 4 1 5 1 4 1 5 5 1 1 5 5 1 1 5 5 5 1 1 5 5 5 5 5 5 5 5 5 5 5 5 5	Start Time	▼           12/28/2020 8:02:00           PM           12/29/2020 9:40:00           AM           12/29/2020 8:25:00           PM           12/30/2020 8:23:00           AM           12/28/2020 5:27:00           PM           12/29/2020 5:31:00	▼           12/28/2020 8:01:00           PM           12/29/2020 9:39:00           AM           12/29/2020 8:24:00           PM           12/30/2020 8:22:00           AM           12/28/2020 5:26:00           PM           12/29/2020 5:30:00	and the second sec	PhaRx, PhaRxMedications: APIX2.5T2 PhaRx, PhaRxMedications: APIX2.5T2 PhaRx, PhaRxMedications: APIX2.5T2 PhaRx, PhaRxMedications: APIX2.5T2 PhaRx, PhaRxMedications: LOVA20TA11 PhaRx, PhaRxMedications:	
Case Identifier Ac00001157 Ac00001157 Ac00001157 Ac00001157 Ac00001157 Ac00001157	♥         Ca           ♥            752         Rx           752         Rx	xNorm:1364435 xNorm:1364435 xNorm:1364435 xNorm:1364435 xNorm:197904 xNorm:197904	Descrip       v       apixaba       Tablet       apixaba       Tablet       apixaba       Tablet       apixaba       Tablet       apixaba       Tablet       Lovasta       Tablet       Lovasta       Tablet       Lovasta       Tablet	an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral an 2.5 MG Oral ttin 20 MG Oral ttin 20 MG Oral	v       administer       administer       administer       administer       administer       administer       administer	red red red red red red red	Televerse.	5	Start Time         ♥           12/28/2020 8:01:00         ♥           PM         12/29/2020 9:39:00           AM         12/29/2020 8:24:00           PM         12/30/2020 8:22:00           AM         12/29/2020 5:26:00           PM         12/29/2020 5:30:00           PM         12/29/2020 5:30:00           PM         12/29/2020 5:50:00	▼           12/28/2020 8:02:00           PM           12/29/2020 9:40:00           AM           12/29/2020 8:25:00           PM           12/30/2020 8:23:00           AM           12/28/2020 5:27:00           PM           12/29/2020 5:31:00           PM           12/30/2020 5:51:00	▼           12/28/2020 8:01:00           PM           12/29/2020 9:39:00           AM           12/29/2020 8:24:00           PM           12/30/2020 8:22:00           AM           12/28/2020 5:26:00           PM           12/29/2020 5:30:00           PM           12/30/2020 5:50:00	and the second sec	PhaRx, PhaRxMedications: APIX2.5T2 PhaRx, PhaRxMedications: LOVA20TA11	

medisolv •



### Medisolv ENCOR - VTE 1 Measure logic Visualizer

#### ENCOR Electronic Measures

Version ENCOR-e

CMS108	v9 - Venous Thromboembolism Prophylaxis
easure Descrip	tion: This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after or surgery end date for surgeries that start the day of or the day after hospital admission.
atient Name: Co	ohen, Laila Medisolv ID: 610ad1d3d682600914f72ffb
atient Result: I	View Patient Details
Qualifying Da	ata Elements
opulation Crit	eria 1
- Initial Patient Popula	tion (view results)
The second second second	
Encounter with Ag	e Range and Without VTE Diagnosis or Obstetrical Conditions"
- Denominator (vi	ow results)
"Initial Population"	
Denominator Exclusion	ons
Numerator (view	v results)
	"Encounter With VTE Prophylaxis Received From Day of Start of Hospitalization To Day After Admission or Procedure" union
	"Encounter With Medication Oral Factor Xa Inhibitor Administered on Day of or Day After Admission or Procedure" intersect
	( "Encounter With Prior or Present Diagnosis of Atrial Fibrillation or VTE"
	union "Encounter With Prior or Present Procedure of Hip or Knee Replacement Surgery"
	) Inion
	Encounter With Low Risk for VTE or Anticoagulant Administered"
union	

olv



# Medisolv ENCOR - Hybrid HWR CCDE Missing Analysis

Clinic	cian - Hospital	- Value Sets Contact U	s													Last EH Load: 1 Last EC Load: 1	
1 Meas	sure Results																
tal: De	emo Hospital 🗸														01/0	1/2021 - 12/31	1/2021
															0170	1/2021 - 12/31	1/2021
atory eCQN	Ms Hybrid Measures	Medisolv eCQMs															
isure Sumn	mary Patient Details																
								Measure Summa	ry								
ag a colu	umn header here to g	roup by that column															
CN	MS Id Measure N	ame				Initial Po	pulation										
	\$					♥											
<b>B</b> CN		al Data Elements for the Hybrid H		Readmission (H	WR)	157											
	Measure wi	th Claims and Electronic Health	Record Data			157											
								Missing Results									
							ā	missing testine									
Drag a	column header here t	o group by that column															
Drag a		o group by that column			Missi	ing						issing %					
CCD		o group by that column			Missi	ing					\ \ \ \	issing %					
		o group by that column			100.000	ing						issing %					1:
CCD		o group by that column			100.000	ing	Patien	t Details – Missi	ng Results		\ \ \ \	issing %					1;
CCD	DE	o group by that column re to group by that column			100.000	ing	Patien	t Details – Missi	ng Results		\ \ \ \	issing %					12
CCD	DE		Age	Payer	100.000	RR	Patien	t Details – Missi SBP	ng Results O2Sat	нст	\ \ \ \	issing % WBC	Na	BiCarb	ĸ	Creat	12 Glucose
CCD HR Drag	g a column header he Patient Name	re to group by that column Medisolv Identifier	2		♥ HR		Temp	SBP	O2Sat	♥	0 19 WT	WBC	Na V	<b>▽</b>	o 0	7	Glucose
CCD HR Drag	DE g a column header he Patient Name Tuchman, Maxim	re to group by that column Medisolv Identifier 610ad1cad682600914f4fdef	67	MEDICARE	♥ HR	RR	Temp           *           99.8 f	SBP	025at	38 %	•           19           •	<b>WBC</b> 9.9	-	26 mmol/L	• .1 mmol/L	1.25 mg/dL	Glucose
CCD HR Drag	g a column header he Patient Name Tuchman, Maxim Maclean, Charles	re to group by that column Medisolv Identifier © 610ad1cad682600914f5126e	¢ 67 83	MEDICARE	♥ HR	RR	Temp           *           99.8 f           97.9 f	SBP	O2Sat	♥ 38 % 43.1 %	0 19 WT	<b>WBC</b> 9.9 6.9	-	<b>▽</b>	• .1 mmol/L	7	Glucose
CCD HR Drag	g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian	re to group by that column Medisolv Identifier 610ad1cad682600914f4fdef 610ad1cbd682600914f5126e 610ad1d1d682600914f656b	67 67 83 77	MEDICARE MEDICARE MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f	SBP           V         V           161 mm[Hg]         97 mm[Hg]           159 mm[Hg]         159 mm[Hg]	025at	38 %           43.1 %           37.1 %	•           19           •	<b>WBC</b> 9.9 6.9 12.6	-	26 mmol/L 32 mmol/L	<ul> <li>4.1 mmol/L</li> <li>4.9 mmol/L</li> </ul>	0 0 0 1.25 mg/dL 1.48 mg/dL	Glucose 107 mg/d 90 mg/dL
CCD HR Dray	DE g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian DeQuincey, Erich	re to group by that column Medisolv Identifier © 610ad1cad682600914f5126e	67 67 83 77	MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f           98.2 f	SBP           V         V           161 mm[Hg]           97 mm[Hg]           159 mm[Hg]           140 mm[Hg]	025at	38 %           43.1 %           37.1 %           38 %	•           19           •	WBC 9.9 6.9 12.6 7.1	-	26 mmol/L	• .1 mmol/L	1.25 mg/dL	Glucose 107 mg/d 90 mg/dL
CCD HR Drag	DE g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian DeQuincey, Erich	re to group by that column Medisolv Identifier 610ad1cad682600914f4fdef 610ad1cbd682600914f5126e 610ad1d1d682600914f656b	67 83 77 65	MEDICARE MEDICARE MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f	SBP           V         V           161 mm[Hg]         97 mm[Hg]           159 mm[Hg]         159 mm[Hg]	025at	38 %           43.1 %           37.1 %	•           19           •	<b>WBC</b> 9.9 6.9 12.6	-	26 mmol/L 32 mmol/L	<ul> <li>4.1 mmol/L</li> <li>4.9 mmol/L</li> </ul>	0 0 0 1.25 mg/dL 1.48 mg/dL	Glucose 107 mg/d 90 mg/dL
CCD HR Dray	DE g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian DeQuincey, Erich Plotnik, Brady	re to group by that column Medisolv Identifier 610ad1cad682600914f4fdef 610ad1cbd682600914f5126e 610ad1d1d682600914f6b56b 610ad1ced682600914f5d7d9	¢ 67 83 77 65 74	MEDICARE MEDICARE MEDICARE MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f           98.2 f	SBP	025at	38 %           43.1 %           37.1 %           38 %	•         •           19         •           •         •	WBC 9.9 6.9 12.6 7.1	-	© 26 mmol/L 32 mmol/L 29 mmol/L	<ul> <li>4.1 mmol/L</li> <li>4.9 mmol/L</li> <li>3.8 mmol/L</li> </ul>	1.25 mg/dL 1.48 mg/dL 0.96 mg/dL 1.26 mg/dL	Glucose 107 mg/d 90 mg/dL 96 mg/dL
CCD HR Dray Q Q Q Q Q Q	DE g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian DeQuincey, Erich Plotnik, Brady Cohen, Laila	re to group by that column Medisolv Identifier 610ad1cad682600914f4fdef 610ad1cbd682600914f5126e 610ad1cbd682600914f5b56b 610ad1ced682600914f5d7d9 5af439c6b7e0fd4d04aec70d	¢ 67 83 77 65 74 85	MEDICARE MEDICARE MEDICARE MEDICARE MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f           98.2 f	SBP           V         V           161 mm[Hg]           97 mm[Hg]           159 mm[Hg]           140 mm[Hg]	025at	38 %           43.1 %           37.1 %           38 %	•         •           19         •           •         •	WBC 9.9 6.9 12.6 7.1	-	© 26 mmol/L 32 mmol/L 29 mmol/L	<ul> <li>4.1 mmol/L</li> <li>4.9 mmol/L</li> <li>3.8 mmol/L</li> </ul>	0.96 mg/dL	Glucose 107 mg/d 90 mg/dL 96 mg/dL
CCD HR Drag	DE g a column header he Patient Name Tuchman, Maxim Maclean, Charles Unset, Marian DeQuincey, Erich Plotnik, Brady Cohen, Laila Aitken, Lainey	re to group by that column Medisolv Identifier © 610ad1cad682600914f5126e 610ad1cbd682600914f5126e 610ad1cbd682600914f556b 610ad1ced682600914f5d7d9 5af439c6b7e0fd4d04aec70d 610ad1d3d682600914f72ffb	¢ 67 83 77 65 74 85 67	MEDICARE MEDICARE MEDICARE MEDICARE MEDICARE MEDICARE	♥ HR	RR	Temp           ♥           99.8 f           97.9 f           97.8 f           98.2 f           98.3 f	SBP	025at	Image: wide wide wide wide wide wide wide wide	•         •           19         19           •         •	<b>WBC</b> 9.9 6.9 12.6 7.1 42.2	-		<ul> <li>4.1 mmol/L</li> <li>4.9 mmol/L</li> <li>3.8 mmol/L</li> <li>3.9 mmol/L</li> </ul>	© © © 1.25 mg/dL 1.48 mg/dL 0.96 mg/dL 1.26 mg/dL 0.78 mg/dL	Glucose 107 mg/d 90 mg/dL 96 mg/dL



# Questions?

*Email: <u>HospitalQuality@crisphealth.org</u>* 

#### THANK YOU!

Next meeting: April 20, 2022

email questions/comments: <u>hscrc.quality@maryland.gov</u>




35

#### APPENDIX ............. ..... .....



# Maryland's Unique Healthcare Payment System



Strengths of the Maryland Health Model:

- Enables **cost containment** for the public
- Ensures all-payer hospital charges correlate with costs
- Guarantees equitable funding of Uncompensated Care
- Creates **transparency and cost savings** for the public and a **stable financing system** for hospitals
- Funds investments in population health
- Establishes Maryland as a leader in linking quality and payment
- Provides support for pioneering state healthcare infrastructure and subject matter expertise
- Incentivizes care transformation across all settings of care
- Invests in primary care
- Allows for innovation



# The Model Allows for Innovation

The Model directly supports hospital-led innovations that improve care delivery and health outcomes in several ways, including:

Hospital regulated margins have increased by approximately 50% under the global budget system.

HSCRC policies consider volumes of highly innovative services separately to ensure adequate funding.

- GBRs guarantee stable revenue even as avoidable utilization decreases, resulting in increased funding available for hospitals to invest in innovations that improve care and help manage health.
- HSCRC data indicates that hospitals are currently using most of these excess margins to subsidize physicians.

HSCRC's CDS-A Drug Funding policy\*

 Funds new innovations in pharmaceuticals that affect all hospitals.

#### HSCRC's Complexity and Innovation policy\*

 Supports academic medical centers (AMCs) leadership in developing emerging therapies and technologies.

\*See policy slides for further details



# **Innovative Drug Funding**



#### **CDS-A: How it Works**

- The CDS-A is a schedule that measures volume and changes in use of certain high-cost physicianadministered outpatient drugs (mostly oncology and infusion drugs).
- Under the CDS-A, HSCRC worked with stakeholders to establish a standard Statewide list of high use, high costs drugs that is updated annually and includes pre-populated templates for each hospital.



#### HSCRC adjusts GBRs:

- Prospectively through the annual update factor to reflect differentially higher inflation for innovative drugs identified in the CDS-A
- Retrospectively to adjust the GBR for the change in the volume of these drugs from the prior period (50% permanent, 50% one-time)

Together, these approaches ensure funding at 100% of Average Sales Price (or 340-B prices for 340-b hospitals).



# **Complexity & Innovation Policy**

# How it Works

- Adjusts GBR to
   support highly
   specialized,
   innovative care in
   Maryland.
- Creates a prospective budgetary amount for certain cases deemed high intensity or innovative based on historical growth (e.g. organ transplant cases, CAR-T).

#### **Qualifying Hospitals**

- Academic Medical Centers qualify automatically for this policy because they have more than 500 beds, an intern/resident to bed ratio of .60 or higher, and an Inpatient Case-mix Index greater than 130% of the statewide average.
- Community hospitals can qualify retrospectively if they meet certain requirements.

#### Methodology

- In-state inpatient cases are deemed highly specialized if the qualifying medical centers:
  - Comprise 95% or more of an ICD-10 procedure code
  - Cases have a case-mix index of 1.5 or greater
- Prospective funding amount is equivalent to historical average growth and reflective of 100% variable cost factor for supplies and drugs, 50% for all other charges
- Removes cases from market shift, demographic adjustment, and PAU methodologies

